VEGF165 human

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC)

Glioma-derived endothelial cell mitogen, Vascular Endothelial Growth Factor, Folliculostellate cell-derived growth factor, VPF
MDL number:
Pricing and availability is not currently available.

biological source



expressed in E. coli


≥98% (HPLC)
≥98% (SDS-PAGE)




1.0-7.0 ng/mL

mol wt

~38.2 kDa


pkg of 10 μg

storage condition

avoid repeated freeze/thaw cycles


endotoxin, tested

NCBI accession no.

UniProt accession no.

shipped in

wet ice

storage temp.


Gene Information

human ... VEGFA(7422)

General description

The gene VEGFA (vascular endothelial growth factor A) is a member of VEGF family of growth factors. The gene is localized to human chromosome 6p21.1. It contains eight exons interspaced by seven introns, spanning a length of 14 kb. The critical region of 2.36 kbp in human promoter lacks a consensus TATA box. However, it contains various consensus-binding sites for many transcriptional regulators.

Biochem/physiol Actions

The gene VEGFA (vascular endothelial growth factor A) encodes a secreted mitogen that is found to participate in physiological and pathological angiogenesis. It serves as a growth factor for endothelial cells and functions in the formation of new blood vessels during embryonic development and adulthood. It binds to two tyrosine kinase receptors VEGFR1 and VEGFR2 and functions in angiogenesis and maintenance of vasculature.

Physical form

Lyophilized with no additives.


Reconstitute in water to a concentration of 0.1-1.0 mg/mL. This solution can then be diluted into other aqueous buffers.
Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
VEGFA is necessary for chondrocyte survival during bone development.
Zelzer E
Development, 131, 2161-2171 (2004)
Genetic variants on chromosome 6p21.1 and 6p22.3 are associated with type 2 diabetes risk: a case-control study in Han Chinese.
Lu F
Journal of Human Genetics, 57, 320-325 (2012)
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors.
Lee S
The Journal of Cell Biology, 169, 681-691 (2005)
Vivian Lehmann et al.
Biotechnology progress, 35(2), e2745-e2745 (2018-11-14)
The only cure available for Type 1 diabetes involves the transplantation of islets of Langerhans isolated from donor organs. However, success rates are relatively low. Disconnection from vasculature upon isolation and insufficient rate of revascularization upon transplantation are thought to...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.